The ADAM9 Knockout HT29 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population featuring gene disruption of ADAM9 in the HT29 human colon adenocarcinoma cell line. This heterogeneous pool of mutant cells provides a robust loss-of-function model for studying ADAM9-dependent processes without the biases inherent in clonal selection. The polyclonal format ensures representation of diverse knockout mutations, enabling robust functional assays in cancer biology and signal transduction research.
HT29 cells were isolated from a primary colon adenocarcinoma of a 44-year-old Caucasian female and are widely used as an intestinal epithelial model. These cells can differentiate into enterocyte-like cells under specific conditions, making them valuable for studying epithelial barrier function and colorectal cancer biology. They retain key signaling pathways, including EGFR and TGF?? cascades, and their well-characterized growth and adherent properties facilitate knockout model generation and downstream functional analyses.
ADAM9 is a sheddase that cleaves membrane-bound HB-EGF and TNF??, releasing soluble ligands that activate EGFR and downstream MAPK and PI3K-Akt pathways. Its disintegrin domain binds integrins ??6??1 and ??v??5, triggering FAK-Src-p130Cas-paxillin signaling to promote adhesion and migration. Upstream regulators include EGF, TGF??, IL-1??, hypoxia, and transcription factors AP-1 and NF-??B. ADAM9 also interacts with tetraspanins CD9 and CD81, modulating its protease and adhesive functions. Activation of EGFR via ADAM9-dependent shedding stimulates Ras-Raf-MEK-ERK and PI3K-Akt cascades, driving proliferation and survival.
In HT29 cells, ADAM9 knockout allows dissection of its role in colorectal cancer progression, where it is often overexpressed. Loss of ADAM9 in this intestinal epithelial background enables analysis of altered EGFR signaling, integrin-mediated adhesion, and migratory capacity. HT29 cells provide a relevant context to study ADAM9??s contribution to epithelial-mesenchymal transition and therapeutic resistance mechanisms. This polyclonal model also facilitates investigation of ADAM9-dependent cross-talk with the tumor microenvironment, providing insights into metastasis and inflammation-associated pathologies.
Researchers can utilize these cells for Transwell migration/invasion assays, cell adhesion studies, and phospho-EGFR analysis to monitor EGFR activation. Proliferation assays (MTT), flow cytometry, RNA-seq, and RT-qPCR enable comprehensive phenotypic characterization. The knockout model is valuable for drug resistance studies, particularly exploring responses to EGFR inhibitors or chemotherapeutics. These polyclonal ADAM9 knockout cells are also suitable for studying integrin signaling dynamics through FAK and Src phosphorylation analyses. By comparing with parental HT29 cells, scientists can dissect the specific contributions of ADAM9 to colorectal cancer invasion and metastasis. For further information, contact Ascent Research.
